FDA panel recommends withdrawing Avastin indication for breast cancer treatment
An FDA advisory panel recommended in late June that Avastin should not be used to treat breast cancer.
An FDA advisory panel recommended in late June that Avastin should not be used to treat breast cancer.
FDA’s Oncology Drug Panel voted unanimously that Avastin’s approval for breast cancer treatment be withdrawn. During the hearings, patient groups such as the Abigail Alliance fought for continued use of Avastin in breast cancer treatment.
Avastin was first approved in 2004 to treat advanced colon cancer and has since been approved for lung, kidney, and brain cancers. FDA proposed withdrawing Avastin’s approval to treat metastatic breast cancer in late 2010, saying that there was not enough evidence to show that the drug is safe and effective for breast cancer treatment.
Avastin’s manufacturer, Genentech, a subsidiary of Roche, lobbied FDA and Congress for a second hearing on the issue in late December. Avastin generates more than $6 billion a year for the company, according to news reports.
The advisory panel recommendation does not signify a final FDA decision. FDA’s public comment period on Avastin withdrawal remains open until July 28, 2011. Sometime after that, FDA Commissioner Margaret Hamburg will make a final decision on use of Avastin use for breast cancer.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
